7 results
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
IDSA Recommendations ... Note: Systemic antifungals ... candida #mucosal #IDSA ... opportunistic #infections #HIVAIDS ... #pharmacology
Overview of antifungal agents benefits, weaknesses, and adverse effects in the treatment of Coccidioidomycosis.
Fluconazole - Low
Overview of antifungal ... effects in the treatment ... Coccidioidomycosis #coccidioides ... #antifungals #comparison ... #table #pharmacology
IDSA - Clinical Strategy to Build an Individualized Treatment Regimen for Multi-Drug Resistant Tuberculosis (MDR-TB)
 •
IDSA - Clinical ... Individualized Treatment ... antimicrobials #regimens #pharmacology ... #dosing #idsa # ... drugs #steps
Antifungal agents benefits, weaknesses, and adverse effects in the treatment of Coccidioidomycosis
Fluconazole
 - Benefits: Low cost/tolerable
Antifungal agents ... effects in the treatment ... Coccidioidomycosis #pharmacology ... #management #treatment ... #coccidioides
IDSA Recommendations for Treating Cytomegalovirus Infections in HIV-AIDS
Preventing CMV Disease:
 • CMV end-organ disease is best
IDSA Recommendations ... Disease: • CMV end-organ ... best prevented by using ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
IDSA Recommendations ... Guidelines for dosing ... Tuberculosis #TB #IDSA ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Disseminated Mycobacterium Avium Complex in HIV-AIDS
Preventing 1st Episode of Disseminated
IDSA Recommendations ... to Table 5 for dosing ... #Prevention #Treatment ... opportunistic #infections #HIVAIDS ... #pharmacology